Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials
OncLive,
Maurie Markman, MD Oncology clinical and research communities and the FDA have increasingly recognized that progression-free…
Maurie Markman, MD Oncology clinical and research communities and the FDA have increasingly recognized that progression-free…
In Partnership With: A core component of any type of therapeutic research is to enhance clinical benefit.
In RCTs, EFS, defined as the primary end-point, has some advantages over OS, as it requires a small sample size, shorter follow-u…
In Partnership With: Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable…